Ophthalmology Therapeutics: Does current pipeline innovation hold the potential to affect the future ophthalmology market?

This Frontier Pharma: Ophthalmology Therapeutics assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products.

Pune, India - March 14, 2018 /MarketersMedia/ —

The pipeline is varied in terms of molecular targets and molecule types. Products acting on the immune system and neurotransmitter signaling are the most prevalent, but no single target dominates by any clear margin. There are a total of 194 first-in class pipeline products in development for ophthalmologic indications 38% of the 512 pipeline products for which there is a disclosed molecular target. Encompassing gene therapies, slowing of the visual cycle and antisense therapies, the pipeline appears robust and has huge potential to strengthen treatment options for ophthalmological disorders.

Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs

Reasons To Buy
• Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
• Visualize the composition of the ophthalmological disorders market in terms of dominant molecule types and targets, and understand the current unmet needs and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
• Analyze the ophthalmological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating ophthalmological disorders to overcome the overwhelming level of unmet need.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
• Identify commercial opportunities in the ophthalmological disorders deals landscape by analyzing trends in licensing and co-development deals, and a curated list of ophthalmological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Get this report at: https://www.themarketreports.com/report/buy-now/935550

In the past the ophthalmological disorders therapy area has suffered from a lack of full understanding of the pathophysiology and underlying mechanisms of the diseases. However, as this knowledge has improved vastly in recent years, potential targets have been identified for treatment. As well as the main disorders previously mentioned, there is also interest in developing treatments for indications such as allergic conjunctivitis and retinitis pigmentosa. The approval of a gene therapy for retinitis pigmentosa is indicative of this progress, and represents the first gene therapy approved for an inherited condition by the FDA.

Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935550

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/ophthalmology-therapeutics-does-current-pipeline-innovation-hold-the-potential-to-affect-the-future-ophthalmology-market/314326

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs%20%20

Source: MarketersMedia

Release ID: 314326

More Press Releases

Global stocks tumble after new Trump tariff threat

Jun 19, 2018

BEIJING — Global stock markets fell Tuesday after U.S. President Donald Trump escalated a dispute with China over technology policy by threatening a tariff hike on an additional $200 billion of Chinese goods. KEEPING SCORE: Germany's DAX was down a sharp 1.3 percent to 12,673 and France's CAC 40 fell 1.1 percent to 5,394. London's FTSE 100 lost 0.4 percent to 7,598. Wall Street looked poised for heavy losses, with the future for the Dow Jones industrial average off 1.3 percent and that for the Standard & Poor's 500 index down 1.1 percent. ASIA'S DAY: The losses were even heavier...

Asian stocks tumble after new Trump tariff threat

Jun 19, 2018

BEIJING — Asian stocks tumbled Tuesday after U.S. President Donald Trump escalated a dispute with Beijing over technology policy by threatening a tariff hike on additional Chinese goods. KEEPING SCORE: The Shanghai Composite Index fell 2.3 percent to 2,953.54 points and Hong Kong's Hang Seng lost 2 percent to 29,685.28. Tokyo's Nikkei 225 retreated 0.9 percent to 22,482.89 and Seoul's Kospi lost 0.8 percent to 2,356.57. Markets in Taiwan, New Zealand and Southeast Asia also declined. Sydney's S&P-ASX 200 gained 0.3 percent to 6,123.00. TRADE TENSIONS: Trump directed the U.S. Trade Representative to prepare new tariffs on $200 billion in...

Markets Right Now: Stocks look to recover from early skid

Jun 19, 2018

NEW YORK — The latest on developments in financial markets (all times local): 4:00 p.m. Stocks are closing mixed Monday after recovering from early losses. Energy stocks helped the comeback. Chevron gained 1.5 percent, getting a boost from a 1.2 percent rise in the price of U.S. crude oil. Some big technology shares also posted gains. Alphabet, the parent company of Google, rose 2.1 percent. Smaller and more U.S.-focused companies climbed higher. The Russell 2000 index added 0.5 percent to a record 1,692.45. Health care companies weighed on the market, however. Pharmaceutical and biotechnology companies fell. Household goods companies took...

World stocks slide over trade tensions, German politics

Jun 19, 2018

SINGAPORE — Global stocks dropped Monday on concerns over trade as the U.S. and China scheduled the start of tariffs on each other's goods, and a row over migrants threatened the German government. Markets in China and Hong Kong were closed for a holiday. KEEPING SCORE: Germany's DAX lost 1.3 percent to 12,839 and France's CAC 40 shed 1.2 percent to 5,433. Britain's FTSE 100 dipped 0.4 percent to 7,605. Wall Street was poised to open lower. Dow futures dropped 0.7 percent and the S&P 500 futures were down 0.6 percent. U.S.-CHINA TARIFFS: Tariffs mooted by the world's two biggest...

US stocks and bond yields dip amid trade worries

Jun 19, 2018

NEW YORK — U.S. stocks closed out a whirlwind week with a modest loss Friday as markets gauged how much to fret about the Trump administration's decision to step up the trade dispute between the world's two biggest economies. The White House announced tariffs on $50 billion of imports from China, and China's almost-immediate response was a promise to retaliate with its own of the same scale. Stocks sank from the start of trading, and the S&P 500 was down 0.7 percent at one point before paring its loss as the day progressed. At the close, the S&P 500 was...

Subscribe to our newsletter!

Your Name

Your Email Address